Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Costs of conservative management of early-stage prostate cancer compared to radical prostatectomy-a claims data analysis.

Brandes A, Koerber F, Schwarzkopf L, Hunger M, Rogowski WH, Waidelich R.

BMC Health Serv Res. 2016 Nov 18;16(1):664.

2.

Long-term health care costs for prostate cancer patients on androgen deprivation therapy.

Krahn MD, Bremner KE, Luo J, Tomlinson G, Alibhai SM.

Curr Oncol. 2016 Oct;23(5):e443-e453.

3.

Single-institution comparative study on the outcomes of salvage cryotherapy versus salvage robotic prostatectomy for radio-resistant prostate cancer.

Vora A, Agarwal V, Singh P, Patel R, Rivas R, Nething J, Muruve N.

Prostate Int. 2016 Mar;4(1):7-10. doi: 10.1016/j.prnil.2015.11.002.

4.

Active surveillance for prostate cancer.

Romero-Otero J, García-Gómez B, Duarte-Ojeda JM, Rodríguez-Antolín A, Vilaseca A, Carlsson SV, Touijer KA.

Int J Urol. 2016 Mar;23(3):211-8. doi: 10.1111/iju.13016. Review.

5.

Financial toxicity: a potential side effect of prostate cancer treatment among Australian men.

Gordon LG, Walker SM, Mervin MC, Lowe A, Smith DP, Gardiner RA, Chambers SK.

Eur J Cancer Care (Engl). 2017 Jan;26(1). doi: 10.1111/ecc.12392.

6.

Understanding the Racial and Ethnic Differences in Cost and Mortality Among Advanced Stage Prostate Cancer Patients (STROBE).

Chhatre S, Bruce Malkowicz S, Sanford Schwartz J, Jayadevappa R.

Medicine (Baltimore). 2015 Aug;94(32):e1353. doi: 10.1097/MD.0000000000001353.

7.

Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy.

Den RB, Yousefi K, Trabulsi EJ, Abdollah F, Choeurng V, Feng FY, Dicker AP, Lallas CD, Gomella LG, Davicioni E, Karnes RJ.

J Clin Oncol. 2015 Mar 10;33(8):944-51. doi: 10.1200/JCO.2014.59.0026. Erratum in: J Clin Oncol. 2015 Apr 20;33(12):1416.

8.

Active surveillance for low-risk prostate cancer compared with immediate treatment: a Canadian cost comparison.

Dragomir A, Cury FL, Aprikian AG.

CMAJ Open. 2014 Apr 24;2(2):E60-8. doi: 10.9778/cmajo.20130037.

9.

Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events.

Krahn MD, Bremner KE, Luo J, Alibhai SM.

Curr Oncol. 2014 Jun;21(3):e457-65. doi: 10.3747/co.21.1865.

10.

The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base.

Martin JM, Handorf EA, Kutikov A, Uzzo RG, Bekelman JE, Horwitz EM, Smaldone MC.

Cancer. 2014 Jul 15;120(14):2114-21. doi: 10.1002/cncr.28697.

11.

Direct cost for initial management of prostate cancer: a systematic review.

Sanyal C, Aprikian AG, Chevalier S, Cury FL, Dragomir A.

Curr Oncol. 2013 Dec;20(6):e522-31. doi: 10.3747/co.20.1630.

12.

Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis.

Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Lee PA, McMahon PM.

Ann Intern Med. 2013 Jun 18;158(12):853-60. doi: 10.7326/0003-4819-158-12-201306180-00002.

13.

Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis.

Cooperberg MR, Ramakrishna NR, Duff SB, Hughes KE, Sadownik S, Smith JA, Tewari AK.

BJU Int. 2013 Mar;111(3):437-50. doi: 10.1111/j.1464-410X.2012.11597.x.

14.

Cognitive changes associated with ADT: a review of the literature.

Jamadar RJ, Winters MJ, Maki PM.

Asian J Androl. 2012 Mar;14(2):232-8. doi: 10.1038/aja.2011.107. Review.

15.

Active surveillance for prostate cancer compared with immediate treatment: an economic analysis.

Keegan KA, Dall'Era MA, Durbin-Johnson B, Evans CP.

Cancer. 2012 Jul 15;118(14):3512-8. doi: 10.1002/cncr.26688.

16.

An update on the changing indications for androgen deprivation therapy for prostate cancer.

Myklak K, Wilson S.

Prostate Cancer. 2011;2011:419174. doi: 10.1155/2011/419174.

17.

Physician social networks and variation in prostate cancer treatment in three cities.

Pollack CE, Weissman G, Bekelman J, Liao K, Armstrong K.

Health Serv Res. 2012 Feb;47(1 Pt 2):380-403. doi: 10.1111/j.1475-6773.2011.01331.x.

18.
19.

The example of CaPSURE: lessons learned from a national disease registry.

Porten SP, Cooperberg MR, Konety BR, Carroll PR.

World J Urol. 2011 Jun;29(3):265-71. doi: 10.1007/s00345-011-0658-3.

20.

Supplemental Content

Support Center